

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Cano et al.

Serial No.: 09/612,925

Filing Date: July 10, 2000

Title: EXPRESSION SYSTEM OF HETEROLOGOUS ANTIGENS AS FUSION
PROTEINS

Examiner: Devi, S.

Art Unit: 1645

Supp Seg
Amend
17/c
Linda
3/18/03

Attorney Docket No.: LEXSA P-13 div2

Commissioner for Patents
Washington, DC 20231**REQUEST UNDER 37 CFR 1.821(e)**

Applicants respectfully request that the enclosed paper copy of the Sequence Listing be entered into the Specification. Please cancel all previously submitted paper copies.

The paper copy of the Sequence Listing submitted herewith is identical to the computer readable copy of the Sequence Listing filed in the parent application, Serial No. 08/930,917, filed September 16, 1997. The content of the paper copy and the computer readable copy are the same. No new matter has been added.

In accordance with 37 CFR 1.821(e), please use the last-filed computer readable form filed in the parent application, Serial No. 08/930,917, as the computer readable form for the instant application, Serial No. 09/612,925. The Patent and Trademark Office is authorized to take all necessary steps to advance and perfect this Request.

The following is a record of the facts underlying this Request.

On or around February 3, 2003, Attorney for Applicants was advised by the Examiner that the CRF copy of the Sequence Listing timely filed on October 16, 2002, was "unreadable." Attorney for Applicant consistently takes great pains to ensure that any Sequence Listing in CRF is undamaged and readable at the time of deposit with the U.S. Postal Service, especially in light of the on-going special requirements related to the receipt of CRF Sequence Listings at the U.S.P.T.O.


In a subsequent teleconference between Attorney for Applicants, the Examiner, and S.P.E. Lowe on March 12, 2003, it was resolved that the CRF copy of the Sequence Listing from the parent application would be used in the instant application, thus precipitating this Request.

As the Response filed on October 16, 2002 was both timely filed and fully compliant with the requirements of 37 C.F.R. 1.821-1.825 at the time of deposit with the U.S. Postal Service, Applicants submit that no fee is required to file this Request.

The Commissioner is authorized to charge any necessary fees or credit any overpayments to Deposit Account No. 10-0100 for Lackenbach Siegel, LLP.

Date: March 12, 2003

Respectfully submitted,
LACKENBACH SIEGEL, LLP
One Chase Road
Scarsdale, NY 10583
(914) 723-4300



Thomas Blankinship
Reg. No. 39,909

LACKENBACH SIEGEL, LLP



One Chase Road
Scarsdale, NY, 10583
U.S.A.

FAX RECEIVED

MAR 13 2003

GROUP 1600

Phone: (914) 723-4300
Fax: (914) 723-4301
E-Mail: mail@lsllp.com

FACSIMILE COVER SHEET**OFFICIAL**Date: **March 12, 2003**To: **Examiner S. Devi
ART UNIT 1645**Facsimile No.: **703 308-4242**From: **Thomas Blankinship**Pages (including cover sheet): **24**Re: **U.S. Patent Application No. 09/612,925 for
EXPRESSION SYSTEM OF HETEROLOGOUS ANTIGENS AS FUSION
PROTEINS**Atty. Ref.: **LEXSA P-13 div 2**

CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being transmitted to the attention of
Examiner S. Devi of Art Unit 1645 at group fax phone number (703) 308-4242 on March
12, 2003 in accordance with 37 CFR 1.6(d).

March 12, 2003 ✓
Date


Thomas Blankinship

CONFIDENTIAL: This message is intended only for the use of the individual or entity to which it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, or have encountered any problem in receiving it, please notify us immediately by telephone. Thank you.